Company news

PDS Biotechnology Corporation news in 2024

PDS Biotechnology Corporation's news releases, calls and decks from 2024, newest first.

View company

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

December 2, 2024

PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results

November 13, 2024

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8: 30 a.m. Eastern Time

November 5, 2024

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

October 21, 2024

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

October 1, 2024

PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

September 15, 2024

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

September 8, 2024

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

September 2, 2024

PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results

August 12, 2024

PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting

August 7, 2024

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

August 6, 2024

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024

August 4, 2024

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

July 31, 2024

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

July 30, 2024

PDS Biotech to Participate at BTIG Virtual Biotechnology Conference

July 28, 2024

PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer

June 11, 2024

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

May 14, 2024

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

May 8, 2024

PDS Biotech to Participate in Upcoming May 2024 Investor Conferences

May 8, 2024

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

May 6, 2024

PDS Biotechnology Announces Details of Virtual KOL Event

May 2, 2024

PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

May 1, 2024

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

April 22, 2024

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

March 26, 2024

PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results

March 19, 2024

PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®

March 12, 2024

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

January 21, 2024

PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference

January 15, 2024

Calls in 2024

Decks in 2024